Vertex Pharmaceuticals Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; unaudited, compared with Q1 2019. Vertex is a pharmaceutical company focused on cystic fibrosis (CF), with additional clinical and preclinical programs in genetic and other therapies.
Financial highlights
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $1,515.1 million | $858.4 million | Up 76% |
| Operating income | $720.2 million | $276.8 million | Up 160% |
| Net income | $602.8 million | $268.6 million | Up 124% |
| Diluted earnings per share | $2.29 | $1.03 | Up from prior year |
| Operating cash flow | $815.7 million | $324.8 million | Up $490.9 million |
- Revenue mix: TRIKAFTA generated $895.2 million, versus no sales in Q1 2019. SYMDEKO/SYMKEVI revenue was $173.2 million (down 46%), ORKAMBI $234.1 million (down 20%), and KALYDECO $212.6 million (down 13%).
- Margins: Cost of sales was approximately 11% of product revenue in both periods. Operating margin was approximately 47.5% versus 32.2%; net margin was approximately 39.8% versus 31.3%.
- Expenses: Research and development rose 32% to $448.5 million; sales, general and administrative expense rose 24% to $182.3 million. Management cited pipeline investment, collaboration and asset-acquisition payments, and launch support.
- Non-operating items: Other expense, net, was $61.1 million, compared with $42.6 million of income in Q1 2019, principally reflecting changes in strategic investment values. The company recorded a $39.4 million unrealized loss on corporate equity securities in Q1 2020, primarily related to CRISPR.
- Liquidity: Cash, cash equivalents and marketable securities totaled $4.19 billion at March 31, up $382.1 million from year-end 2019. Working capital was $3.91 billion. Cash and cash equivalents were $3.59 billion.
- Debt and obligations: No borrowings were outstanding under the $500 million revolving credit facility; the company reported compliance with its covenants. Long-term finance lease liabilities were $533.0 million. Total liabilities were $2.43 billion.
- Capital returns: Vertex repurchased $300.0 million of stock in Q1, with $164.0 million remaining under its $500 million authorization. Financing cash outflows also included $136.2 million for shares withheld for employee tax obligations.
Material changes and management commentary
- Revenue growth was primarily driven by TRIKAFTA’s October 2019 U.S. approval and launch. Management said the majority of approximately 18,000 eligible U.S. patients had initiated treatment by the filing date.
- Management cautioned that Q1 product sales benefited from early prescription refills, advance purchasing and initial compliance and persistence among new TRIKAFTA patients; these factors may not recur. Sales of older CF medicines declined partly as U.S. patients switched to TRIKAFTA.
- The company reported that COVID-19 had not affected medicine demand or supply to date, but had delayed certain research and development activities and shifted most employees to remote work. It warned that future effects could include pressure on net prices, research, operations and financial performance.
- Some clinical trial screening or enrollment was paused or delayed to protect patients and ease healthcare-system burdens. Vertex reported a temporary pause in screening and enrollment for its VX-814 Phase 2 AAT-deficiency trial; the trial remained active.
- Outlook was positive on liquidity: Vertex expected existing funds and product-sale cash flows to fund operations for at least the next 12 months and did not expect COVID-19 to adversely affect liquidity. The filing provides no specific numerical revenue or earnings guidance.
- Pipeline and regulatory milestones included ongoing EMA review of the TRIKAFTA application, recent submissions in Australia and Switzerland, and a planned second-half 2020 FDA submission for eligible children ages 6–11 if Phase 3 results were positive. Vertex also expected further CTX001 trial data during 2020 and anticipated starting T1D patient clinical development in late 2020 or early 2021.
- Potentially material uncertainties include regulatory approval and reimbursement, clinical-trial outcomes and delays, COVID-19’s duration and effects, and volatility in strategic equity investments. The company reported no material legal proceedings or material accrued contingent liabilities. It had agreed to repay the French government in 2020 a portion of amounts collected under ORKAMBI early-access programs; the filing does not state a clear amount.
Important facts for investors to verify
- Whether TRIKAFTA uptake and revenue remain strong after the temporary early-refill and advance-purchasing effects, and how ex-U.S. approvals and reimbursement progress.
- Whether COVID-19 delays, trial pauses or changes in payer mix affect pipeline timelines, product pricing, demand or supply.
- How strategic-investment fair-value movements affect reported earnings; Q1 2020 net income included substantial non-operating volatility.
- R&D spending, collaboration milestones and other pipeline commitments, including potential Exonics contingent payments and the undisclosed amount of the French repayment.
- Execution of remaining share repurchases and future liquidity needs alongside lease obligations and planned research and development investment.